Subscribe to unlock this article
Thanks for your support.
Jorge Oriol launched Rigi Capital in the first half of 2023. After nearly three years of searching, he has successfully acquired Super’s Diana, a company operating in the animal health sector. The transaction was led by Aurica Search Fund (its second acquisition in this sector following its participation in the buyout of Alfavet, a German company specialized in nutraceuticals for pets), with the participation of other investors such as Moonbase Capital, Itaca Capital Partners, ICF (Institut Català de Finances), and Karim Zahran, among others. The enterprise value was approximately €15M, with around 50% senior debt leverage.
Founded more than 30 years ago and headquartered near Barcelona, Super’s Diana develops, manufactures, and markets medicines and supplements for swine, cattle, and poultry livestock, operating in more than 30 countries. In 2024, the company generated €17.6M in sales and EBITDA of €3.1M.
The investment responds to a business succession process resulting from the upcoming retirement of the owner, Francisca Margarit, following a track record marked by growth and profitability.
“Super’s Diana has a very solid business foundation, a team with deep technical expertise, and a very close relationship with its customers. The priority is to ensure continuity of the project and continue developing it with a long-term vision,” Oriol highlighted.
According to Margarit, the company’s owner until now, “after more than 30 years leading Super’s Diana, I approach this new stage with peace of mind, knowing the company is in good hands. Rigi Capital shares the values that have guided the project throughout all these years, and I fully trust they will continue its development and take it to the next level, while maintaining commitment to the team, customers, and our way of doing business.”
The company’s growth plan combines organic growth—boosting exports and strengthening commercial capabilities—with inorganic growth aimed at expanding the product portfolio and enhancing profitability. In this context, Karim Zahran, an executive with extensive experience in the pharmaceutical sector, joins the project not only as an investor, but also as an active board member leading the inorganic growth strategy.
DD: KPMG / Legal (buyer): Barrilero / AVQ / M&A: CS Corporate Advisors / Legal (seller): Cases & Lacambra
